Eva Wagner

Transfer of minimally manipulated CMV-specific T cells from stem cell or third-party donors to treat CMV infection after allo-HSCT

Michael Neuenhahn, Julia Albrecht, Marcus Odendahl et al. · Leukemia · 2017 · 161 citations · Full text

Medicine, Immunology, Infectious Diseases +12

Safety and Immunogenicity of Modified Vaccinia Ankara-Bavarian Nordic Smallpox Vaccine in Vaccinia-Naive and Experienced Human Immunodeficiency Virus-Infected Individuals: An Open-Label, Controlled Clinical Phase II Trial

Edgar T. Overton, Jack T. Stapleton, Ian Frank et al. · Open Forum Infectious Diseases · 2015 · 142 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +16

A Randomized, Double-Blind, Placebo-Controlled Phase II Trial Investigating the Safety and Immunogenicity of Modified Vaccinia Ankara Smallpox Vaccine (MVA-BN®) in 56-80-Year-Old Subjects

Richard N. Greenberg, Christine M. Hay, Jack T. Stapleton et al. · PLoS ONE · 2016 · 81 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +17

Immunogenicity and safety of three consecutive production lots of the non replicating smallpox vaccine MVA: A randomised, double blind, placebo controlled phase III trial

Edgar T. Overton, Steven J. Lawrence, Eva Wagner et al. · PLoS ONE · 2018 · 66 citations · Full text

Veterinary Medicine, Cardiology, Immunology +17

A Phase I Dose-Escalation Trial of BN-CV301, a Recombinant Poxviral Vaccine Targeting MUC1 and CEA with Costimulatory Molecules

Margaret E. Gatti‐Mays, Julius Strauss, Renee N. Donahue et al. · Clinical Cancer Research · 2019 · 61 citations · Full text

Life Sciences, Immunology, Immunotherapy +13